Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 14, pp. 1265-1276
Closed Access | Times Cited: 133

Showing 26-50 of 133 citing articles:

Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting
Filippo de Marinis, Andrea Ardizzoni, Ilaria Attili, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 110-110
Open Access
Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia
Wendy A. Cooper, Benhur Amanuel, Caroline Cooper, et al.
Pathology (2025)
Open Access
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives
Lucrezia Barcellini, Simone Nardin, G. Sacco, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 652-652
Open Access
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
Giannis Mountzios, Stephanie P.L. Saw, Lizza E.L. Hendriks, et al.
Cancer Treatment Reviews (2025) Vol. 134, pp. 102902-102902
Closed Access
A comparative evaluation of alectinib for ALK-positive non-small-cell lung cancer: A systematic review
Monica Kharat, Harshitha Nookala, Jabez David John, et al.
Medicine (2025) Vol. 104, Iss. 7, pp. e41506-e41506
Open Access
A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment
Rui Fu, Chao Zhang, Mengmeng Song, et al.
Cancer Letters (2025) Vol. 616, pp. 217595-217595
Closed Access
InDuRanS beim lokal fortgeschrittenen NSCLC
Cas Stefaan Dejonckheere, Eleni Gkika
Forum (2025)
Closed Access
Prognose bei Lungenkrebspatienten mit/ohne therapierbare Alterationen unterschiedlich?
Daniel Hamberger
Pneumo News (2025) Vol. 17, Iss. 1, pp. 22-23
Closed Access
Gender and Geographic Characteristics Among Thoracic, GI, and Breast Oncology Editorial Boards: Disparities and Measures to Address Gaps
Robert Hsu, Zhaohui Arter, David J. Benjamin
JCO Global Oncology (2025), Iss. 11
Open Access
Multimodale Therapiekonzepte beim lokal fortgeschrittenen NSCLC
Martin Metzenmacher, Gregor Zaun, Filiz Özkan, et al.
TumorDiagnostik & Therapie (2025) Vol. 46, Iss. 02, pp. 113-116
Closed Access
Lung Cancer: Targeted Therapy in 2025
Nicole Bouchard, Nathalie Daaboul
Current Oncology (2025) Vol. 32, Iss. 3, pp. 146-146
Open Access
Evaluating Diagnostic and Treatment Timelines for Alk-Positive Nsclc Patients: Results from a Global Registry
Hisham Bazzi, Nicholas Thuo, S Sravanam, et al.
(2025)
Closed Access
Case report: Alectinib-associated intestinal ulceration and colitis in a patient with non-small cell lung cancer and effective treatment with Mesalazine
Zijian Qiu, Ke Fei, Xiaoping Zhu
Pathology & Oncology Research (2025) Vol. 31
Open Access
Pathological Examination and Genetic Mutation Testing: Bridging Their Best Practices Using MINtS
Hiroyoshi Tsubochi, Koichi Hagiwara
Respirology (2025)
Closed Access
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”
Marco Donatello Delcuratolo, Veronica Crespi, Giorgio Saba, et al.
Cancer Treatment Reviews (2025) Vol. 135, pp. 102918-102918
Open Access
Carcinoma de pulmón de célula no pequeña
Y. Lage, Miguel García-Pardo, M.E. Olmedo, et al.
Medicine - Programa de Formación Médica Continuada Acreditado (2025) Vol. 14, Iss. 27, pp. 1580-1594
Closed Access
Update 2025: Management of Non‑Small-Cell Lung Cancer
Hyein Jeon, Shuai Wang, Junmin Song, et al.
Lung (2025) Vol. 203, Iss. 1
Open Access
Remote results of treatment of patients of the Russian population with stage I–II non-small cell lung cancer (results of the observational study CARL-001)
К. К. Лактионов, В. В. Бредер, А. К. Аллахвердиев, et al.
Meditsinskiy sovet = Medical Council (2025)
Open Access
Place des thérapies ciblées en situation adjuvante au cours des cancers bronchiques non à petites cellules localisés
Nicolas Girard
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S46-3S51
Closed Access
Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging Applications
Laurenţia Galeş, Mihai-Andrei Păun, Ioana Butnariu, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3123-3123
Open Access
Réarrangement de ALK dans le cancer pulmonaire non à petites cellules
G. Naulleau, Gary Birsen, Audrey Mansuet‐Lupo, et al.
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S86-3S94
Closed Access
Traitement par immunothérapie péri-opératoire des cancers bronchiques non à petites cellules résécables
Mariona Riudavets, Gary Birsen, J. Slomka, et al.
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S39-3S45
Closed Access
Sexual health and reproductive toxicity from cancer therapies
David J. Benjamin, Mark P. Lythgoe
The Lancet Oncology (2025) Vol. 26, Iss. 4, pp. 408-410
Closed Access
Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatment
B. Munárriz, Sam Khan, Y Q Li, et al.
Cancer (2025) Vol. 131, Iss. S1
Closed Access
Treatment of non–small cell lung cancer with RET rearrangements
Hui Jing Hoe, Benjamin Solomon
Cancer (2025) Vol. 131, Iss. S1
Open Access

Scroll to top